Results 181 to 189 of about 13,244 (189)

Dolutegravir

Reactions Weekly, 2016
openaire   +1 more source

Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients

HIV Clinical Trials, 2014
G Nichols, B Wynne
exaly  

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

HIV Medicine, 2017
exaly  

Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection

Annals of Pharmacotherapy, 2014
Staci M Lockhart, Misty M Miller, Michelle D Liedtke   +2 more
exaly  

Synthesis and Characterization of Potential Impurities of Dolutegravir: A HIV Drug

ChemistrySelect, 2018
Naveen Mulakayala
exaly  

Population pharmacokinetics of dolutegravir in HIV‐infected treatment‐naive patients

British Journal of Clinical Pharmacology, 2015
Jianping Zhang, Brian M Sadler, Sherene Min   +2 more
exaly  

Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review

Annals of Pharmacotherapy, 2018
Rosaleen Boswell, Michelle M Foisy, Christine A Hughes   +2 more
exaly  

Emergence of Acquired Dolutegravir Resistance in Treatment-experienced People With HIV in Lesotho

Clinical Infectious Diseases
Lipontso Motaboli, Mpho Kao, Mathebe Kopo   +2 more
exaly  

Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program

Viruses
Pachawo Bisani, Carrie M Cox, Sam Phiri   +2 more
exaly